Patients with BPS are more likely to experience dystonias in other parts of the body than patients with other focal dystonias 7 . Complaints of dry eye and photophobia are usually reported, but the exact nature of this association remains unestablished 5 . Finally, concerning the genetic pattern and inheritance of BPS, it seems that there is a higher frequency of focal dystonia in relatives, however with a considerable phenotypic variability 8 . The purpose of this study was to evaluate the demographic and clinical features, including outcomes of botulinum toxin treatment in patients with BPS referred to a Brazilian tertiary care center. Additionally, clinical characteristics of isolated blepharospasm were compared to those of blepharospasm plus other movement disorder.
METHODS

Patients and data acquisition
This was a retrospective study, from 1993 to 2010, of 125 consecutive patients with BPS seen at the Movement Disorder Unit of the Universidade Federal de São Paulo (São Paulo, Brazil). During those 17 years, clinical data were recorded in a systematic manner, using a standard clinical protocol. Each case, on the first consultation and subsequent follow-up, was evaluated by an unblinded movement disorder specialist. Incomplete or ambiguously recorded files were not included.
All patients had a detailed neurological examination to rule out other underlying neurological conditions. The criteria for diagnosis of BPS included observation of involuntary bilateral increased blinking with intermittent dystonic eyelid and eyebrow contractions. Patients diagnosed with apraxia of eyelid opening were not included in this study. The severity of BPS was accessed according to the Jankovic rating scale 9 .
Clinical protocol
The primary aim of this study was to evaluate clinical features and therapeutic outcomes of patients with BPS treated with botulinum toxin injections. Our secondary objective was to compare aforementioned variables between patients with and without associated movement disorders, particularly oromandibular dyskinesia and other focal dystonias.
The following demographic data were recorded: gender, ethnicity (Caucasian, Asian and African Brazilians), age at last appointment and at symptom onset, disease duration, affected site at onset, associated movement disorder, triggering factors, family history of dystonia and previous history of head trauma. History of hypertension, alcohol intake or tobacco use were also recorded.
Informations regarding the oral and surgical treatment for blepharospasm were documented. Two different commercial brands of botulinum toxin (BTX-A) were used throughout the study (Botox ® and Dysport ® ), according to the product availability at the time of treatment. Standard doses of BTX-A were used on eye region whenever possible (Botox ® 60UI and Dysport ® 200UI). Additional sites were used if the previous sites had lead to side effects or less effectiveness or the presence of associated movement disorders other than BPS. Treatment response was gauged based on the relief of symptoms between first and last injections.
All subjects signed the informed consent, which explained the treatment and also authorized publication of their data. This study was approved by the ethical committee of Universidade Federal de São Paulo (CEP number 1171/11).
Statistical analysis
Normality requirements for data distribution were confirmed using Kolmogorov-Smirnov test. Continuous data is presented as mean (±) standard deviation, and categorical data as absolute (n) or relative frequency (%). Comparisons between groups were carried out using Student's t-test for continuous variables, whereas Pearson Chi-square test was used for contingency tables. Correlations between independent variables were done using Pearson test. Linear regression analysis was also performed in order to adjust for confounding variables. A corrected p-value of 0.05 was set as the threshold for the statistical significance.
RESULTS
A total of 125 subjects were included in this statistical analysis. The epidemiological data and clinical features are presented in Table 1 .
In relation to previous medical history, head trauma, including mild, had occurred in 13 subjects (10.4%) before the onset of BPS. High blood pressure was present in 39.2% individuals, smoking in 20%, and heavy alcohol consumption in 8.8%. Glaucoma was present in only 4 (3.2%) patients. Diagnosis of previous psychiatric disease occurred in 8% of subjects, predominantly depression; 12 (9.6%) subjects reported previous use of neuroleptic drug. Two patients were previously diagnosed with Myasthenia Gravis (MG), and the coexistence of both diseases (BPS and MG) is a valid possibility. Brain CT or MRI was conducted in 25 patients (20%), but no significant abnormality was found. Most patients presented with mild periventricular abnormalities, characteristics of microangiopathy.
Before reporting to our center, 71 (56.8%) patients had taken oral medications for treatment of blepharospasm without significant improvement. The most frequently used drugs were: benzodiazepines (54.9%), anticholinergics (33.8%) and antidepressants (25.3%). In addition to clinical treatment, ten patients had surgical treatment for BPS, such as blepharoplasty and myectomy.
From a total of 125 subjects, 113 (90.4%) were treated with BTX-A. The severity of contractions in eyebrow and eyelid, before and after first BTX-A injection, is presented in Figure. A total of 906 BTX-A injections were performed (mean 8/ patient; range=2-24 injections). The difference between severity of BPS in both sites, before and after BTX-A injection was statistically significant, as shown in Figure. The mean duration of BTX-A effect after first injection was 3.1 months. After subsequent injections and adjustment of dosage and site, the duration of effect could be improved to 3.3 months (p=0.60). Side effects after treatment occurred in 14% of patients, and the most frequently reported were ptosis, blurred vision, diploplia and felling of "foreign body" in eyes.
The patients were further categorized into two groupsthe ones with isolated BPS and the ones with BPS plus (BPS+) other movement disorders, such as oral dyskinesia, oromandibular dystonia, spasmodic dysphonia and cervical dystonia -in order to figure out if there were clinical differences between them. The comparison between BPS versus BPS+ groups is presented in Table 2 . As showed, no statistically significant differences were found between patients in both groups, except for disease duration before being referred.
DISCUSSION
BPS is a primary adult-onset dystonia of unknown etiology, but multiple environmental and genetic factors are likely implicated 10 . This study was undertaken to explore different clinical correlation of the disease, which could provide clues as to the etiopathogenesis. The discussion that follows is divided into two sets; firstly, we discuss BPS demographic and clinical features, and then its therapeutic outcomes comparing to literature data.
Demographic and clinical features
Our patients presented the same average age, sex and ethnicity distribution as reported elsewhere 11, 12 . The majority of patients had onset in the eye region, and almost 40% developed spread during the follow up. This is an interesting observation since the mean time of follow up was about six years, and some patients were followed during more than ten years. When asked about triggering factors, most patients reported stress and anxiety, followed by photophobia and light to be more relevant. Moreover, few subjects reported previous ocular disease, such as glaucoma. A recently published well designed study found an evidence of ocular disease such as dry eye, blepharitis and keratoconjuctivitis in 50 of 140 patients with BPS 10 . Previous studies have showed non-significant associations between alcohol use, hypertension and minor head trauma (without loss of consciousness) with BPS 13 . On the other hand, head trauma with loss of consciousness 13 and as a protective caffeine intake 14 , have been suggested as a risk factor and as a protective factor, respectively. The lack of a control group in our study precluded confirmation of those associations.
Concerning the family history of dystonia, we found a positive history reported by 8.8% of patients. We have to highlight that this data was acquired through patient report and that their family members were not examined in our center. Positive family history in previously published articles ranged from 7 to 32%, according to distinct methodology and population studied 8, 12, 13, 15 .
When patients with isolated BPS were compared with patients with BPS+, such as Meige syndrome, craniocervical dystonia and laryngeal dystonia, no significant differences were found, showing that those disorders are probably spectrum of the same disorder. In BPS+ group, BPS was the first presentation in 91.2% and subsequently spread to lower face, neck or vocal cords. BPS has the highest likelihood for further spread, occurring in about 33.3%, followed by dystonia of upper extremities, torticollis and laryngeal dystonia 16 .
Therapeutic outcomes
In our series, 113 out of 125 patients were treated with BTX-A. As showed in Figure, the severity of BPS improved either in the eyebrow or eyelid. There were significant differences in BPS severity in each site before and after BTX. This response was evaluated in first injection, and, even thought we did not analyze the response in all subsequent injections, most of patients presented the same therapeutic effect during follow up. According to a recent systematic review on botulinum toxin for BPS, although BTX is a highly safe treatment for BPS, information about best regimen treatment, injections techniques and formulations are not clear 17 .
In this study, we did not find significant differences with regard to the duration of symptom relief after BTX injection. The mean time of follow up was about 72 months, but some patients were seen throughout 10 years, and we did not find any case with secondary resistance to BTX-A.
In a previous Brazilian study, 30 patients with BPS under BTX-A treatment were evaluated and about 93% of them had symptom improvement, with maintenance of relief duration in the time of follow up and low incidence of side effect 18 . On Figure. Severity of blepharospasm before and after first botulinum toxin injection. *Severity 0: no visible contraction. Severity 1: increased blinking present with external stimuli. Severity 2: mild but spontaneous fluttering, definitely noticeable, possibly embarrassing, but not functionally disabling. Severity 3: moderate, very noticeable spasm, mildly incapacitating. Severity 4: severe, incapacitating spasm.
